Latest by Alan Franciscus
A study was conducted to evaluate the reliability and validity of several survey instruments that will be used in the PROP UP study to understand patient-reported symptoms before, during and after HCV treatment.
This fact sheet will describes transmission routes of hepatitis C and how to prevent its transmission.
Every year there is always a lot of noteworthy news and information about hepatitis C, and the trend continued in 2017.
"Like it or not, if we are ever going to eliminate hepatitis C, we are going to have to test and treat prisoners," Alan Franciscus writes.
Phase 2a results were announced in a study to understand the safety and to determine an effective dose of the combination of odalasvir, AL-335 with and without simeprevir to treat HCV genotype 1 treatment-naive patients.
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
"The Veterans Affairs Healthcare system is a perfect place to test for 'real world' results," Alan Franciscus writes. "How do the direct-acting antiviral drugs work in a 'real world' setting as opposed to clinical trials?"
An important study was recently published in Lancet Gastroenterology & Hepatology holds the promise of changing the way that people with hepatitis C are treated.
Consequences of Inaccurate Hepatitis C Virus Genotyping on the Costs of Prescription of Direct Antiviral Agents in an Italian District
Researchers conducted a study to analyze commercial hepatitis C genotype/subtype assays to understand the cost-effectiveness of potential errors in the assays.
There is a 30% to 35% difference in the genetic make-up of the nucleotide sites of the hepatitis C virus that is used to classify the different genotypes. This viral diversity is what makes it so difficult to develop one drug to treat all of the geno...